- Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumorsZhou, Q.; Wu, Y-L.; Li, J.; Liu, A.; Cui, J.; Kuboki, Y.; Yamamoto, N.; Han, S-W.; Lin, G.; Sun, J-M.; Wu, L.; Zhu, Z.; Shuang, J.; Qiu, F.; Shi, W.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- FIH phase I dose escalation and dose expansion study of anti-EGFR ADC MRG003 in patients with advanced solid tumorsQiu, M.; Guo, Y.; Guo, W.; Nian, W.; Liao, W.; Xu, Z.; Zhang, W.; Zhang, Y.; Wei, X.; Xue, L.; Tang, W.; Wu, Y.; Ren, G.; Wang, L.; Xi, J.; Wang, Y.; Li, M.; Hausheer, F.; Hu, C.; Xu, R.Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2021-09-16 To 2021-09-21.
- First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumorsWang, Yakun; Gong, Jifang; Lin, Rongbo; Zhao, Shen; Wang, Jufeng; Wang, Qianli; Zhang, Yanqiao; Su, Dan; Zhang, Jingdong; Dong, Qian; Lin, Ling; Tian, Wen; Chen, Ying; Yang, Yang; Zhang, Xueyuan; Wan, Xuechao; Gao, Jinfeng; An, Na; Jansen, Valerie Malyvanh; Shen, LinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors
8阅读
